跳至主要内容
临床试验/CTRI/2025/07/091845
CTRI/2025/07/091845尚未招募不适用

Study of incidence, resistance patterns, efficacy of ceftazidime-avibactam and aztreonam in critically ill patients with carbapenem resistant enterobacterales (CRE) infection in a tertiary care setup- A prospective observational study

BLK MAX SUPERSPECIALITY OSPITAL1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2025年8月8日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
84
试验地点
1
主要终点
TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU

研究概览

简要总结

study of incidence, resistance patters, efficacy of ceftazidime-avibactam and aztreonam in critically ill patients with carbap[enem resistant enterobacterales infection in tertiary care setup-a prospective observational study

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 未提供

排除标准

  • PREGNANT PATIENTS PATIENT UNLIKELY TO SURVIVE BEYOND 48 HOUR CANCER DIAGNOSIS IMMUNOSUPPRESSIVE/ANTI CANCER THERAPY.

结局指标

主要结局

TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU

时间窗: TO FIND THE INCIDENCE OF CRE INFECTION AND 28 DAY MORTALITY IN ADULT PATIENTS ADMITTED IN MICU

次要结局

  • TO STUDY THE TIME TO MICROBIOLOGICAL AND CLINICAL CURE IN ADULT PATIENTS WITH CRE IN ICU
  • TO STUDY THE RISK FACTORS, ANTIBIOTIC SUSCEPTIBILITY AND RESISTANCE PATTERN (MIC VALUE AND BREAK POINTS) IN ADULT PATIENTS WITH CRE IN ICU
  • TO STUDY THE FOLLOWING(synergy between CAZ-AVI+ATM)

研究者

发起方
BLK MAX SUPERSPECIALITY OSPITAL
申办方类型
Private hospital/clinic
责任方
Principal Investigator
主要研究者

priyanka sagar

BLK MAX SUPERSPECIALITY HOSPITAL

研究点 (1)

Loading locations...

相似试验